ALLO Allogene Therapeutics

Allogene Therapeutics (ALLO) Down 1.6% Since Last Earnings Report: Can It Rebound?

01:43 ET

Allogene Unveils Dagger Technology During R&D Showcase

11-30 12:00 ET

Allogene Therapeutics to Hold a Research and Development Showcase

11-28 05:40 ET

Oppenheimer Emerging Biotech Analysts to Hold Analyst/industry Conference Call

11-28 04:45 ET

We're Hopeful That Allogene Therapeutics (NASDAQ:ALLO) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although Amazon.com made losses for many years after listing, if you had bought and held the

11-28 06:00 ET

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Shares Sold by Cibc World Market Inc.

Cibc World Market Inc. reduced its position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Rating) by 7.3% in the 2nd quarter, according to the company in its most recent 13F filing wit

11-25 04:41 ET

HC Wainwright Lowers Allogene Therapeutics (NASDAQ:ALLO) Price Target to $29.00

Allogene Therapeutics (NASDAQ:ALLO – Get Rating) had its target price lowered by HC Wainwright from $43.00 to $29.00 in a report issued on Monday, The Fly reports.

11-25 03:31 ET

FY2022 Earnings Forecast for Allogene Therapeutics, Inc. (NASDAQ:ALLO) Issued By HC Wainwright

Allogene Therapeutics, Inc. (NASDAQ:ALLO) – Investment analysts at HC Wainwright lifted their FY2022 earnings estimates for Allogene Therapeutics in a report issued on Monday, November 21st.

11-24 01:21 ET

Allogene Therapeutics, Inc. (NASDAQ:ALLO) to Post Q1 2023 Earnings of ($0.70) Per Share, HC Wainwright Forecasts

Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Rating) – Research analysts at HC Wainwright issued their Q1 2023 EPS estimates for Allogene Therapeutics in a research report issued on Monday, November 21st. HC Wainwright analyst R. Burns expects that the company will earn ($0.70) per share for the quarter. HC Wainwright has a "Buy" rating and a $29.00 price objective on the stock.

11-23 02:34 ET

Wall Street Analysts Believe Allogene Therapeutics (ALLO) Could Rally 137%: Here's Is How to Trade

11-22 11:30 ET